1. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma
- Author
-
Andrés Castellanos-Martín, A. Blanco Gómez, Javier Cañueto, Jesús Pérez-Losada, E. Cardeñoso, Juan Luis García, Angel Santos-Briz, Emilia Fernández-López, Concepción Román-Curto, Ministerio de Ciencia e Innovación (España), European Commission, Instituto de Salud Carlos III, Junta de Castilla y León, Fundación Eugenio Rodríguez Pascual, Instituto de Investigación Biomédica de Salamanca, Obra Social Kutxa, Fundación Sandra Ibarra - Solidaridad Frente al Cáncer, and Ministerio de Economía y Competitividad (España)
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Skin Neoplasms ,Dermatology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Biomarkers, Tumor ,Carcinoma ,Humans ,Medicine ,Basal cell carcinoma ,Epidermal growth factor receptor ,Stage (cooking) ,Lymph node ,Aged, 80 and over ,biology ,business.industry ,Cancer ,Prognosis ,medicine.disease ,Immunohistochemistry ,ErbB Receptors ,medicine.anatomical_structure ,Real-time polymerase chain reaction ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Disease Progression ,Cancer research ,biology.protein ,Female ,business - Abstract
[Background]: Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans after basal cell carcinoma, and its incidence is dramatically rising. CSCC is rarely problematic, but given its high frequency, the absolute number of complicated cases is also high. It is necessary to identify molecular markers in order to recognize those CSCCs with poor prognosis. There is controversy concerning the role of epidermal growth factor receptor (EGFR) as a marker of prognosis in CSCC. In addition, EGFR-targeted therapies have emerged in recent years and a better understanding of the role of EGFR in CSCC may be of help for some patients in predicting prognosis and guiding curative management. [Objectives]: To evaluate the role of EGFR as a prognostic factor in CSCC. [Methods]: We evaluated clinical and histopathological features, including events of poor clinical evolution, in a series of 94 cases of CSCC. We also analysed EGFR expression by immunohistochemistry, fluorescent in situ hybridization and quantitative polymerase chain reaction. [Results]: We detected EGFR in 85 cases (90%), with overexpression in 33 cases (35%), and aberrant EGFR expression in the cytoplasm in 50 cases (53%). EGFR overexpression in the primary tumours was associated with lymph node progression, tumour–nodes–metastasis stage progression and proliferation (Ki-67 staining) in CSCC. EGFR overexpression and poor grade of differentiation were the strongest independent variables defining lymph node metastasis and progression in CSCC in a logistic regression model. [Conclusions]: We demonstrate that EGFR overexpression has prognostic implications associated with lymph node metastasis and progression in CSCC., J.P.‐L. was partially supported by FEDER and MICINN (PLE2009‐119, SAF2014‐56989‐R), Instituto de Salud Carlos III (PI07/0057, PI10/00328, PIE14/00066), Junta de Castilla y León (SAN673/SA26/08, SAN126/SA66/09, SA078A09, CSI034U13, BIO/SA31/15), IBSAL (IBY15/00003), the ‘Eugenio Rodríguez Pascual’, the ‘Fundación Inbiomed’ (Instituto Oncológico Obra Social de la Caja Guipozcoa‐San Sebastian, Kutxa) and the ‘Fundación Sandra Ibarra de Solidaridad frente al Cáncer’. C.R.‐C. is funded by Q3718001E (2009‐2010) and GRS 612/A/11 (2011‐2012) and ‘the Fundación Eugenio Rodríguez Pascual’. A.C.‐M. was supported by FIS (PI07/0057) and MICINN (PLE2009‐119).
- Published
- 2017
- Full Text
- View/download PDF